REASSURE Program for Breast Cancer Follow-Up Care
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new program called REASSURE, designed to improve follow-up care for low-risk breast cancer survivors. It aims to ensure survivors feel more prepared for life after cancer treatment. The study compares this new approach with usual care to determine which is more effective. Suitable participants include those diagnosed with stage I breast cancer (an early-stage cancer) 6-24 months ago and willing to use email for study tasks. As an unphased trial, this study offers a unique opportunity to enhance follow-up care for breast cancer survivors.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the study team or your doctor.
What prior data suggests that the REASSURE intervention is safe for breast cancer follow-up care?
Research has shown that the REASSURE program offers a new approach to support low-risk breast cancer survivors in their follow-up care. This program aims to simplify care and reduce stress for patients. Although specific safety data from past studies on this program is unavailable, the "Not Applicable" phase label typically indicates that it does not involve testing a drug or treatment with potential side effects. Instead, it likely involves a change in care delivery, which is generally considered safe. For concerns, discussing them with a doctor can provide more insight into what to expect.12345
Why are researchers excited about this trial?
Researchers are excited about the REASSURE Program because it offers a fresh approach to breast cancer follow-up care. Unlike the usual follow-up care, which typically involves regular physical exams and imaging, the REASSURE Program aims to provide a more personalized and supportive follow-up experience for patients. This program could improve patient satisfaction and overall well-being by incorporating tailored support and communication strategies. Researchers hope to find out if this approach enhances patient outcomes and quality of life compared to standard care practices.
What evidence suggests that the REASSURE intervention is effective for breast cancer follow-up care?
Research shows that follow-up care, such as the REASSURE program studied in this trial, can greatly benefit breast cancer survivors. Participants in this trial will receive either the REASSURE Follow-Up Care or Usual Follow-Up Care. Studies indicate that personalized follow-up programs, especially those led by nurses, help manage life after cancer by reducing unnecessary treatments and focusing on what matters most. Effective follow-up care includes clear summaries of treatment, advice on healthy eating and exercise, and information on side effects and signs of cancer recurrence. These programs aim to improve quality of life and detect any return of cancer early. Overall, well-organized follow-up care is essential for supporting breast cancer survivors over the long term.16789
Who Is on the Research Team?
Heather Neuman
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
This trial is for low-risk breast cancer survivors who were diagnosed with stage I, ER and/or PR positive, her2neu negative breast cancer in the past 6-24 months. Participants must be able to use email and read/write in English without cognitive impairments. Pregnant individuals or those who received chemotherapy for their diagnosis are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive the REASSURE intervention, which includes a PRO assessment, follow-up visit recommendations, and survivorship messaging
Follow-up
Participants are monitored for quality of follow-up care, healthcare utilization, and survivorship experiences
What Are the Treatments Tested in This Trial?
Interventions
- REASSURE
Trial Overview
The REASSURE intervention is being tested to see if it can improve preparedness for survivorship care among low-risk breast cancer survivors by optimizing necessary care while reducing unnecessary treatments. The study will involve 100 participants over an 18-month period.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Citations
REASSURE Program for Breast Cancer Follow-Up Care
The research suggests that follow-up care, including nurse-led and tailored follow-up programs, can be effective in managing breast cancer survivors by reducing ...
Follow-up care for breast cancer survivors: improving patient ...
Preferred follow-up care elements included treatment summary, information on nutrition/exercise, expected side effects, signs and symptoms of recurrence, ...
a 12-month electronic patient-reported outcomes follow-up ...
The study reveals moderate adherence to 12-month ePROs follow-up assessments in invasive early breast cancer and DCIS patients, with response rates ranging ...
Follow-up of early breast cancer in a public health system
Overall survival, detection of breast cancer (BC) recurrence, and quality of life (QoL) are critical parameters for assessing the effectiveness of surveillance ...
Systematic review of clinical practice guidelines for long- ...
While hormone receptor-positive (HR+) breast cancer can recur decades after diagnosis, HR-negative tumours have a very low recurrence rate ...
Study Details | Remote Electronic Assessment of Survivors ...
This study tests a novel, risk-stratified approach for low risk breast cancer survivor follow-up care that reduces burden for survivors and their ...
Follow-up after treatment for breast cancer
To offer FPs a summary of evidence-based recommendations to guide their follow-up survivorship care of women treated for breast cancer.
Enhancing Early-Stage Breast Cancer Survivorship
Park et al found that 90% of second breast cancers were detected with a 2-year surveillance interval and DeBruhl et al found no contralateral ...
Rethinking breast cancer follow-up based on individual risk ...
Data from the Surveillance, Epidemiology, and End Results Program (SEER) program shows that the 5-year relative survival rate is 90.4% for luminal, 83.6 ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.